Kymera Therapeutics KYMR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$315M-30.8% | -$311.35M-39.1% | -$295.12M-76.2% | -$275.43M-74.5% | -$240.88M-55.8% | ||
| $8.29M+4.1% | $8.31M+12.7% | $8.27M+31.7% | $8.11M+56.3% | $7.96M+91.9% | ||
| $61.68M+7.7% | $59.9M+8.9% | $59.25M+13.7% | $58.35M+19.4% | $57.28M+25.3% | ||
| —— | $3.86M— | —— | —— | —— | ||
| $2.93M-17.0% | -$1.97M-543% | -$988K-157% | -$629K-124% | $3.54M+3,499% | ||
| —— | —— | —— | —— | —— | ||
| $13.77M— | $7.43M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $17.55M— | -$34.92M— | ||
| -$242.58M-3.6% | -$232.89M-19.7% | -$227.93M-71.7% | -$251.01M-120% | -$234.06M-120% | ||
| $1.42M-76.8% | $1.45M-88.9% | $2.28M-90.4% | $2.1M-93.4% | $6.09M-83.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$712.52M— | -$521.06M— | —— | —— | —— | ||
| $19.19M— | $0— | —— | —— | —— | ||
| $1.64M+5.1% | $1.49M-5.2% | $1.37M— | $1.59M— | $1.56M— | ||
| $1.01B+295% | $990.71M+62.7% | $288.26M-52.6% | $499.67M+39.9% | $255.35M-28.5% | ||
| $54.13M+1,620% | $236.76M+2,205% | $2.24M-92.5% | $268.18M+1,657% | -$3.56M-108% | ||
| $300K+28.2% | $312K+51.5% | $299K+56.5% | $270K+55.2% | $234K+47.2% | ||
| —— | $3.86M-21.7% | $4.12M+11.6% | $4.39M+78.3% | $4.66M+278% | ||
| —— | —— | —— | -$1.7M— | $17.97M— | ||
| -$5.25M— | -$5.04M— | —— | —— | —— | ||
| -$2.61M-0.5% | -$2.67M-4.9% | -$2.73M+29.9% | -$2.66M+33.3% | -$2.6M+39.3% | ||
| —— | $18K+106% | -$64K+73.3% | -$146K+13.6% | -$228K-131% | ||
| —— | —— | —— | $9.13M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | -$656.23M— | -$492.17M— | -$328.12M— | -$164.06M— | ||
| $80.28M+857% | $61.62M+423% | $14.96M+47.0% | $15.47M+194% | $8.39M+58.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $1.03M-62.5% | $1.46M-29.2% | $1.89M+37.5% | $2.31M+237% | ||
| -$244M-1.7% | -$234.34M-13.0% | -$230.21M-55.3% | -$252.92M-83.4% | -$239.96M-76.0% | ||
| -$244M-1.7% | -$234.34M-13.0% | -$230.21M-55.3% | -$252.92M-83.4% | -$239.96M-76.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
